Drug intelligence / Profile preview

FT@XBP1

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

FT@XBP1 is a nanoparticle-based siRNA delivery system that targets macrophage-specific *Xbp1* deficiency. The formulation uses folic acid-modified D-α-tocopheryl polyethylene glycol 1000 succinate (FA-TPGS) nanoparticles to deliver siRNA against X-box binding protein 1 (XBP1) to hepatic macrophages, thereby inhibiting XBP1 expression. This targeted silencing shifts macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, reduces pro-inflammatory factor release, and alleviates hepatic steatosis, liver injury, and fibrosis. Its primary experimental indication is metabolic dysfunction-associated steatohepatitis (MASH)[1].

Brand names: FT@XBP1
Other names: FT + XBP1

Targets

XBP1 (X-box-binding protein 1)

Beyond the preview

Go deeper on FT@XBP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT@XBP1.

Explore the full profile